facebook
twitter
rss
account
search
search

FDA approves generic Requip tablets

May 12, 2008 at 10:14 AM   |   Comments

WASHINGTON, May 12 (UPI) -- The U.S. Food and Drug Administration has approved the first generic versions of a drug designed for the treatment of restless legs syndrome.

The FDA said it approved Requip (ropinirole hydrochloride) in dosages of 0.25 milligrams, 0.5 milligrams, 1 milligram, 2 milligrams, 3 milligrams and 4 milligrams.

The marketing approval went to Roxane Laboratories Inc., Teva Pharmaceuticals USA, Par Pharmaceuticals Inc. and Mylan Pharmaceuticals Inc.

While Requip is also FDA-approved to treat symptoms of Parkinson's disease, the generic products aren't approved for that purpose because that is protected by patent. However, the FDA said the patent expires this month, at which time manufacturers of the generic drugs may seek approval for that use.

© 2008 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Dinosaurs shrank for 50 million years before becoming birds
2
Music helps cows relax, produce more milk
3
Five-minute video visualizes history of human culture
4
Cape Cod scientists tag first great white shark of season
5
Thousands of velellas wash up on the shores of San Francisco
Trending News
Video
x
Feedback